Impact of previous blinatumomab treatment and disease burden on EFS following CD19 CAR T cells and OS following relapse. EFS, defined as the time from CD19 CAR T-cell infusion to one of the following events: no response, relapse, or death. (A) EFS stratified by blinatumomab-naïve patients (no blina—teal) vs blinatumomab-exposed patients who achieved a CR to blinatumomab (blina-CR—blue) vs blinatumomab-exposed patients who did not achieve a CR to blinatumomab (blina-no CR—red). P values for EFS curves: .59 (no blina vs blina-CR); .01 (blina-CR vs blina-no CR); .001 (no blina vs blina-no CR). (B) EFS stratified by high disease burden (≥5% bone marrow blasts—blue [high]) vs low disease burden (<5% bone marrow blasts—red (low). (C) OS following relapse, stratified by relapse immunophenotype. Median OS for CD19⁺ relapse was 18.9 months (95% CI, 11.2-27.0 months). Median OS for CD19⁻ relapse was 9.7 months (95% CI, 6.9-15.9 months). Median OS for LS was 3.7 months (95% CI, 1.2-7.0 months). Red: CD19⁺; blue: CD19⁻; green: LS. CI, confidence interval; LS, lineage switch. (A-B) Reproduced with permission from Wolters Kluwer Health, license number 5363041439390, from Myers et al²⁰; (C) reproduced with permission from Elsevier, license number 5363050768789, from Lamble et al.²³